Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

GT20029's effectiveness compared to finasteride or RU58841 is still unproven.

Androgenic alopecia thins hair strands by miniaturizing follicles. The pivotal finasteride trials (1,553 men, 1 mg/day, two years) report increased hair counts and improved assessed appearance, but they measured density, not the diameter of individual strands, so the effect on thickness itself is not established.

Cyproterone acetate is not a women-only drug — published reports describe use in men for prostate cancer, paraphilic disorders and gender-affirming therapy — but it is not FDA-approved for any indication, and European regulators restricted higher doses over a dose-related meningioma risk.

One small randomised trial (26 women) found 5% azelaic acid comparable to 2% minoxidil in female pattern hair loss, and the anti-DHT rationale otherwise rests on in-vitro work — community members generally describe azelaic acid as an add-on to minoxidil or finasteride rather than a standalone treatment.

Small published studies and a 2025 meta-analysis report hair-count gains from scalp botulinum toxin injections, but nearly all of them lack control groups, and reviewers of the same literature call the evidence low-quality; the treatment is off-label and not approved for hair loss anywhere.

Regulators and a large French cohort study link higher-dose, long-term cyproterone acetate to meningioma, and its label also lists liver-enzyme and mood effects — so it is not a drug anyone should call safe in the abstract, and its use in gender-affirming care is a prescriber's decision with monitoring.

There is no approved topical dutasteride; it exists only as pharmacy-compounded preparations and small studies, so its effectiveness and long-term safety are not established.

Estradiol helps treat hair loss by balancing hormones and supporting hair follicle health.

One small randomised trial (26 women) found 5% azelaic acid comparable to 2% minoxidil for female pattern hair loss, and the anti-DHT rationale rests on laboratory work; for alopecia areata, telogen effluvium and seborrhoeic dermatitis there is no trial evidence for azelaic acid at all.

Adenosine may help improve hair growth affected by hormonal imbalances like PCOS or DHT.

The standard dosage of dutasteride is 0.5 mg once daily.

No published study has tested alfatradiol together with finasteride or minoxidil, so there is no direct evidence either way — no reported interaction, but also nothing that looked for one. Community members commonly combine them without reporting problems; ask a prescriber before adding a second agent aimed at the same DHT pathway.

Some doctors avoid prescribing dutasteride due to its higher risk of side effects.

Setipiprant blocks the prostaglandin D2 receptor DP2 rather than the DHT pathway that finasteride and dutasteride act on. The one published human trial — a 169-man, 24-week phase 2a study at 2,000 mg a day — reported no statistically significant improvement in hair density over placebo, and setipiprant is not an approved hair-loss medicine anywhere.

White tea may have some benefits, but evidence on DHT reduction is limited.

Clascoterone is a topical treatment that blocks DHT to prevent hair loss.

Baricitinib helps regrow hair by targeting the autoimmune response in alopecia areata.

Procyanidin-based hair tonics may promote hair growth but lack definitive evidence for AGA.

HMI-115 is an investigational anti-prolactin-receptor antibody being trialled for androgenetic alopecia. It is not approved anywhere; its hair-loss evidence is a 16-person Phase 1b announced only by press release, plus a completed 192-man Phase 2 in China whose results are not yet published.

The only published clinical study of fluridil enrolled 43 men, so its use in women is untested rather than established; women considering it should talk to a doctor, and it is not advised in pregnancy or breastfeeding because no reproductive-safety data exists.

Vitamin B5 does not prevent DHT-related androgenic alopecia.

No study has tested follistatin in women or transgender people on hormone therapy, and it has no approved human use or established dose; the one relevant signal, from a 2023 randomized study in adolescents with PCOS, links higher follistatin to less favourable metabolic markers, so the published evidence does not support using it in this group.

Sustained vitamin A intake above the tolerable upper limit (3,000 mcg/day of retinol for adults) is linked in case reports to diffuse hair shedding; the claim that it amplifies DHT-driven hair loss has no published human evidence behind it.

No trial has ever compared topical adenosine in men against women directly, so the claim is unproven. Separate small Japanese trials — 30 women vs placebo over 12 months, 102 men vs niacinamide over 6 months — both reported more thick hairs, so the published evidence is positive in both sexes rather than clearly better in one.

Published studies link tofacitinib mainly to alopecia areata and its severe variants — as an off-label drug being studied for them, not as a cause of hair loss. The evidence is mostly small, open-label or retrospective, and relapse after stopping is commonly reported.

PP405 is not a peptide and does not block DHT: it is an experimental topical gel from Pelage Pharmaceuticals that inhibits the mitochondrial pyruvate carrier, aimed at waking dormant follicles. Its registered Phase 2 trial (NCT06393452) measured safety and tolerability in 78 adults with pattern hair loss; it is not approved and not for sale.

There is no published human study of bicalutamide applied to the scalp for hair loss, no licensed topical product and no established dose, so no result can be predicted from it. The evidence that exists is for the oral tablet in women, which is a prescription drug requiring liver monitoring and contraindicated in pregnancy.

Topical Vitamin D treatments may help some individuals with alopecia.

Setipiprant blocks the DP2 (CRTH2) receptor that prostaglandin D₂ acts through, and PGD₂ is reported to be elevated in balding scalp — but the one published placebo-controlled trial in men (DuBois 2021, n=169) found no significant hair regrowth. It is an experimental compound, not an approved hair-loss medicine.

Tamsulosin is a prescription alpha-1 blocker approved for benign prostatic hyperplasia; no human trial has tested it for hair loss, and there are no dosing protocols or safety data for that use. Its connection to hair is a receptor-biology hypothesis, not a treatment.